RVV Revive Therapeutics Ltd
- 0.010
- -0.005-33.33%
Revive Therapeutics Ltd News
Express News | Revive Therapeutics Ltd - Additional Phase 3 Clinical Trial Data Analyses May Suggest Bucillamine's Potential for Long Covid.
Express News | Revive Therapeutics Ltd - FDA Has Recommended That Evaluation of Bucillamine for Long Covid Be Submitted as a New Ind Application
Express News | Revive Therapeutics Ltd - Company Is Exploring Use of Bucillamine as a Potential Treatment for Long Covid
Express News | Revive Therapeutics Ltd: Would Be Required to Conduct a Clinical Study for De Novo Submission for Possible Approval
Express News | Revive Therapeutics Ltd: FDA Has Determined That Product Should Follow De Novo Regulatory Pathway
Express News | Revive Therapeutics Ltd - Meeting Date Assigned by FDA Is June 7, 2024
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
Revive Therapeutics Ltd. (RVV.CN) on Tuesday provided an update on its clinical study evaluating the safety and feasibility of oral psilocybin as a potential treatment for methamphetamine use disorder
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillami...
Revive Therapeutics To Submit Type C Meeting Request With FDA for Bucillamine to Treat Long COVID
Revive Therapeutics Provides Corporate Update
Revive Therapeutics Explores the Use of Bucillamine for Long COVID
Revive Therapeutics Says Completed Development of a Novel Lyophilized Formulation of Bucillamine
Revive Therapeutics Ltd. (RVV.CSE) said Wednesday said that it has completed the formulation development work of its next-generation lyophilized formulation of Bucillamine (New Bucillamine) conducted
Revive Therapeutics Re-Appoints CEO, CFO
Revive Therapeutics Ltd. (RVV.CSE) said Wednesday that its board has re-appointed Michael Frank as executive chairman and chief executive officer, and Carmelo Marrelli as chief financial officer and c
Revive Therapeutics Collaborates With Attwill Medical Solutions to Develop Novel Lyophilized Formulation of Bucillamine
Revive Therapeutics Ltd. (RVV.CSE) on Monday said it has signed a collaboration agreement with Attwill Medical Solutions LP (AMS) for the clinical and commercial development of the company's next-gene
Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
Revive Therapeutics Ltd. (RVV.CSE), developing therapeutics for medical needs and rare disorders, on Tuesday provided an update on the development of a next generation lyophilized formulation of Bucil
Revive Therapeutics in Agreement With Defence Research and Development Canada to Evaluate Bucillamine for Nerve Agent Exposure
Revive Therapeutics Ltd. (RVV.CSE), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, on Tuesday said it has entered into
Revive Therapeutics Brief: Announcinig Initiation of Novel Bucillamine Formulation Development
06:33 AM EDT, 08/22/2023 (MT Newswires) -- Revive Therapeutics Brief: Announcinig Initiation of Novel Bucillamine Formulation Development
Express News | Revive Therapeutics Brief: Announcing Filing of Patent for Bucillamine in Treatment of Exposure to Chemical Warfare Agents
